Startup Showcase: Movetis – Pioneering GI Disease Treatment

Revolutionizing Gastrointestinal Healthcare with Cutting-Edge Pharmaceuticals

In the world of pharmaceutical innovation, one company is dedicated to making strides in treating gastrointestinal (GI) diseases. Welcome to the Startup Showcase of Movetis, a pioneering pharmaceutical company with a focus on developing groundbreaking treatments for GI conditions.

Movetis: Transforming GI Healthcare

A Leading GI Pharmaceutical Company: Movetis is at the forefront of pharmaceutical research and development for GI disorders. With a deep commitment to enhancing the lives of patients dealing with these conditions, Movetis is driving innovation in the healthcare industry.

Targeting Critical GI Disorders: The company’s primary focus is on developing drugs for the treatment of diseases within the gastrointestinal area. These disorders encompass a wide range of conditions, including severe chronic constipation, ascites, paediatric reflux, and severe forms of GI motility disorders.

Resolor: A Breakthrough in Chronic Constipation: One of Movetis’ key achievements is the development of Resolor, a groundbreaking product designed for the symptomatic treatment of chronic constipation in women. Resolor has shown immense promise and is also being tested for chronic constipation in males and children, opioid-induced constipation, and post-operative ileus.

Innovation Beyond Resolor

Expanding the Product Portfolio: While Resolor is a standout success, Movetis continues to expand its product portfolio. M0002, currently in Phase II trials, aims to treat ascites—an accumulation of fluid caused by liver malfunction. Additionally, M0003 is entering Phase II development to address heartburn and regurgitation in patients refractory to PPIs and pediatric reflux.

Promising Preclinical Portfolio: Movetis boasts two prioritized compounds, M0014 and M0012, along with two compound libraries in its preclinical portfolio. These innovations underline the company’s dedication to pioneering treatments for a variety of GI disorders.

Keep exploring EU Startups  Will TADF Technology Revolutionize the OLED Industry Through Enhanced Efficiency?

Academic Collaborations: To bolster its research efforts, Movetis has established partnership agreements with esteemed institutions like the universities of Ghent, Leuven, and Rotterdam. These collaborations ensure that Movetis remains at the forefront of GI healthcare innovation.

Stay Connected with Movetis

For more information about Movetis and its groundbreaking work in the field of gastrointestinal healthcare, visit their official website and follow them on social media:


Want to amplify your startup’s story? EU Startup News is your launchpad to reach startup founders, investors, and C-level execs across Europe. Discover our tailored promotional strategies such as Sponsored Articles and Partnerships. Click here to learn more or contact us directly at [email protected]. Join us, and let’s make your startup the talk of Europe!

Keep exploring EU Startups  Boosting Automotive Safety and UX: Is AI In-Cabin Monitoring the Answer?
Previous Story

Startup Showcase: SMP – Intelligent Scents

Next Story

Startup Showcase: ProMaterial – Revolutionizing ConstructionTech with Innovative SaaS Solutions